Liu et al presented a histologic staging system for a Breast Implant-Associated Anaplastic Large Cell Lymphoma (BI-ALCL). The authors are from multiple institutions in the United States, China and Australia.
Patient selection: woman with breast implant-associated anaplastic large cell lymphoma
Parameters:
(1) invasion of capsule by lymphoma cells
(2) extension through capsule by lymphoma cells
Invasion of Capsule
Extension Through
Stage
none
absent
T1
superficial infiltration
absent
T2
sheets within
absent
T3
NA
present
T4
Mean progression-free survival (PFS):
(1) Stage T1: 144 months (12 years)
(2) Stage T4: 80 months (6.6 years)
(3) Stages T2 and T3: similar to T4
Presentation with a mass (versus effusion only) was another adverse prognostic factor.
To read more or access our algorithms and calculators, please log in or register.
